Combined with ticagrelor, 50 mg aspirin daily can reduce bleeding events without increasing ischemic risk compared with 75–100 mg aspirin daily in coronary artery disease patients: insights from the TIFU (Ticagrelor in Fuwai Hospital) study

References

• Dobesh PP, Oesterich JH. Ticagrelor: pharmacokinetics, pharmacodynamics, clinical efficacy, and safety. Pharmacotherapy. 2015 34;(10):1077–1090. doi:10.1002/phar.1477.
   Web of Science ®Google Scholar
• Levine GN, Bates ER, Bittl JA, Brindis RG, Fihn SD, Fleisher LA, Granger CB, Lange RA, Mack MJ, Mauri L, et al. 2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: a report of the American College of Cardiology/American Heart Association Task Force on clinical practice guidelines. J Am Coll Cardiol 2016;68:1082–1115. doi:10.1016/j.jacc.2016.03.513.
   PubMed Web of Science ®Google Scholar
• Zanchin T, Temperli F, Karagiannis A, Zanchin C, Räsänen M, Koskinas KC, Stortecky S, Hunziker L, Praz F, Blöchlinger S, Moro C. Frequency, reasons, and impact of premature ticagrelor discontinuation in patients undergoing coronary revascularization in routine clinical practice: results from the bern percutaneous coronary intervention registry. Circ Cardiovasc Interv 2018 May;11(5):e006132. doi:10.1161/CIRCINTERVENTIONS.118.006388.
   PubMed Web of Science ®Google Scholar
• Mehran R, Rao SV, Bhatt DL, Gibson CM, Caixeta A, Eikelboom J, Kaul S, Wiviott SD, Menon V, Nikolsky E, Serebruany V. Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the bleeding academic research consortium. Circulation 2011;123:2736–2747. doi:10.1161/CIRCULATIONAHA.110.009449.
   PubMed Web of Science ®Google Scholar
• Xian Y, Wang TY, McCoy LA, Effron MB, Henry TD, Bach RG, Zettler ME, Baker BA, Fonarow GC, Peterson ED Association of discharge aspirin dose with outcomes after acute myocardial infarction: insights from the treatment with ADP receptor inhibitors: longitudinal assessment of treatment patterns and events after acute coronary syndrome (TRANSLATE-ACS) study. Circulation 2015 Jul 21;132(3):174–181. doi:10.1161/CIRCULATIONAHA.114.014992.
   PubMed Web of Science ®Google Scholar
• Gurbel PA, Bliden KP, Butler K, Tantry US, Gesheff T, Wei C, Teng R, Antonino MJ, Patil SB, Karunakaran A, et al. Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study. Circulation 2009 Dec 22;120(25):2577–2585. doi:10.1161/CIRCULATIONAHA.109.912550.
   PubMed Web of Science ®Google Scholar
• Bonaca MP, Bhatt DL, Cohen M, Steg PG, Storey RF, Jensen EC, Magnani G, Bansilal S, Fish MP, Im K, Bengtsson O. Long-term use of ticagrelor in patients with prior myocardial infarction[J]. N Eng J Med 2015;372(19):1791–1800. doi:10.1056/NEJMoa1500857.
   PubMed Web of Science ®Google Scholar
• Orme RC, Parker WAE, Thomas MR, Judge HM, Baster K, Sumaya W, Morgan KP, McMellon HC, Richardson JD, Grech ED. Wheeldon NMStudy of two dose regimens of ticagrelor compared with clopidogrel in patients undergoing percutaneous coronary intervention for stable coronary artery disease (STEEL-PCI). Circulation 2018;138:1290–1300. doi:10.1161/CIRCULATIONAHA.118.034790.
   Web of Science ®Google Scholar
• Task Force Members, Montalescot G, Sechtem U, Achenbach S, Andreotti F, Arden C, Budaj A, Bugiardini R, Crea F, Cuisset T, Di Mario C, et al. 2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J 2013;34(38):2949–3003. doi:10.1093/eurheartj/eht296.
   PubMed Web of Science ®Google Scholar
• James S, Akerblom A, Cannon CP, Emanuelsson H, Husted S, Katus H, Skene A, Steg PG, Storey RF, Harrington R, Becker R. Comparison of ticagrelor, the first reversible oral P2Y(12) receptor antagonist, with clopidogrel in patients with acute coronary syndromes: rationale, design, and baseline characteristic of the PLATelet inhibition and patient Outcomes (PLATO) trial. Am Heart J 2009;157(4):599–605. doi:10.1016/j.ahj.2009.01.003.
   PubMed Web of Science ®Google Scholar
• Gao R, Wu Y, Liu H, Su G, Yuan Z, Zhang A, Wang Y, Wang Z, Wang Y, Zhang H, Zheng Y. Safety and incidence of cardiovascular events in chinese patients with acute coronary syndrome treated with ticagrelor: the 12-month, phase IV, multicenter, single-arm DAYU study. Cardiovasc Drugs Ther 2018 Feb;32(1):47–56. doi:10.1007/s10557-018-6772-3.
   PubMed Web of Science ®Google Scholar
• Zhao Q, Zhu Y, Xu Z, Cheng Z, Mei J, Chen X, Wang X. Effect of ticagrelor plus aspirin, ticagrelor alone, or aspirin alone on saphenous vein graft patency 1 year after coronary artery bypass grafting a randomized clinical trial. JAMA 2018 Apr 24;319(16):1677–1686. doi:10.1001/jama.2018.3197.
   PubMed Web of Science ®Google Scholar
• Goto S, Huang CH, Park SJ, Emanuelsson H, Kimura T. Ticagrelor vs. clopidogrel in Japanese, Korean and Taiwanese patients with acute coronary syndrome – randomized, double-blind, phase III PHILO study. Circ J 2015;79(11):2452–2460. doi:10.1253/circj.CJ-15-0112.
   PubMed Web of Science ®Google Scholar
• Arora S, Shemisa K, Vaduganathan M, Qamar A, Gupta A, Garg SK, Kumbhani DJ, Mayo H, Khalili H, Pandey A, Das SR. Premature ticagrelor discontinuation in secondary prevention of atherosclerotic CVD: JACC review topic of the week. J Am Coll Cardiol 2019 May 21;73(19):2454–2464. doi:10.1016/j.jacc.2019.03.470.
   PubMed Web of Science ®Google Scholar
• Jolly SS, Pogue J, Haladyn K, Peters RJ, Fox KA, Avezum A, Gersh BJ, Rupprecht HJ, Yusuf S, Mehta SR Effects of aspirin dose on ischaemic events and bleeding after percutaneous coronary intervention: insights from the PCI-CURE study. Eur Heart J 2009;30:900–907. doi:10.1093/eurheartj/ehn417.
   PubMed Web of Science ®Google Scholar
• Mehta SR, Tanguay JF, Eikelboom JW, Jolly SS, Joyner CD, Granger CB, Faxon DP, Rupprecht HJ, Budaj A, Avezum A, et al.Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomized factorial trail. Lancet 2010;376:1233–1243. doi:10.1016/S0140-6736(10)61088-4.
   PubMed Web of Science ®Google Scholar
• Valgimigli M, Bueno H, Byrne RA, Collet JP, Costa F, Jeppsson A, Jüni P, Kastrati A, Kolh P, Mauri L, et al. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: the Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J 2018 Jan 14;39(3):213–260. doi:10.1093/eurheartj/ehx419.
   PubMed Web of Science ®Google Scholar
• Patrono C, Ciabattoni G, Patrignani P, Pugliese FR, Filabozzi PA, Catella FR, Davì GI, Forni LA. Clinical pharmacology of platelet cyclooxygenase inhibition. Circulation 1985;72:1177–1184. doi:10.1161/01.cir.72.6.1177.
   PubMed Web of Science ®Google Scholar
• Patrono C, García Rodríguez LA, Landolfi R, Baigent C. Low-dose aspirin for the prevention of atherothrombosis. N Engl J Med 2005;353:2373–2383. doi:10.1056/NEJMra052717.
   PubMed Web of Science ®Google Scholar
• Vranckx P1, Valgimigli M2, Jüni P, Hamm C, Steg PG, Heg D, van Es GA, McFadden EP, Onuma Y, van Meijeren C, Chichareon P. Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-label, randomised superiority trial. Lancet 2018 Sep 15;392(10151):940–949. doi:10.1016/S0140-6736(18)31858-0.
   PubMed Web of Science ®Google Scholar